Search the Newsreel

Financial Institutions Stock: Still A Cautious Buy With Improved Outlook (NASDAQ:FISI)

Price-Driven Insight from (ZVRA) for Rule-Based Strategy

This article provides a price-driven analysis for Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and an exceptional risk-reward short …

Arcutis (ARQT) Q2 2026 Earnings Call Transcript

₹524: That's What Analysts Think Awfis Space Solutions Limited (NSE:AWFIS) Is Worth After Its Latest Results

Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress

Nektar Therapeutics' stock fell 4% following its Q2 2026 earnings report, despite progress in its autoimmune pipeline, notably rezpegaldesleukin. The market reacted negatively to the company's substantial cash burn, with a quarterly net loss exceeding US$40 million and trailing 12-month losses widening. While the …

Will Rising Revenue But Mounting Losses and Steady Payouts Change Brookfield Wealth Solutions' (BNT) Narrative

Brookfield Wealth Solutions Ltd. (NYSE:BNT) Short Interest Update

How Rapport Therapeutics Inc. (RAPP) Affects Rotational Strategy Timing

This article analyzes Rapport Therapeutics Inc. (RAPP) using AI models to determine its effect on rotational strategy timing. Key findings suggest a strong sentiment supporting an overweight bias, with resistance being tested. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, …

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) reported a Q2 loss of $0.31 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. However, the company missed revenue estimates, posting $5.15 million against an expected $5.43 million. Despite beating EPS estimates two out …

PDF Solutions (PDFS) Posts Stronger Results, Is The Upside Already Priced In?

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker

An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous …

Shanghai Fudan Zhangjiang Bio Pharmaceutical Ltd (SEHK:1349) Stock Profit Rebound Raises Durability Questions

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement

Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals (NASDAQ: ETON) saw its shares rise significantly in pre-market trading after reporting stronger-than-expected second-quarter financial results and providing an optimistic revenue guidance for FY26. The company exceeded analyst consensus estimates for both earnings per share and sales. The article also lists other …

TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …

Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026

Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …

Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?

BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …

ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that invest in Regeneron Pharmaceuticals, Inc. (RGO) stocks. The list, sorted by market value, details each fund's symbol, market value, weight of RGO stock, issuer, management style, focus, expense ratio, assets under management …

Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?

Iovance Biotherapeutics, Inc. stock jumps 130% in 2026 but RSI screams overbought

ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold

ANI Pharmaceuticals (ANIP) is currently in focus after reporting its Q2 and H1 2026 results and reaffirming its full-year net revenue outlook of $1,080 million to $1,140 million. Despite recent strong earnings, the stock has seen a short-term decline, though it shows significant long-term …

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals (IONS) has drawn investor attention after recent share price moves, with the stock up over the past month but down over the past …

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at …

Rigetti Computing Stock (RGTI) Opinions on earnings and CHIPS Act funding

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating

BofA Securities has reiterated its Sell rating on Aardvark Therapeutics (AARD.US). The article does not provide further details regarding the financial implications or the analyst's rationale for maintaining this rating.

Corcept therapeutics chief development officer sells $1.8m in stock

William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $1.85 million on August 10, 2026, through two separate transactions under a 10b5-1 plan. Despite the sales, which occurred while the stock was near its 52-week high, Guyer also acquired …

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Diluted earnings per share (diluted EPS) of Spero Therapeutics, Inc. – BMV:SPRO

Eton Pharmaceuticals Stock Soars After Huge Q2 Beat And Target Hikes

Eton Pharmaceuticals (ETON) stock surged by 45.78% after reporting a significant Q2 beat, with non-GAAP EPS of $0.43 and revenue of $37.6M, driven by 99% year-over-year growth. The company also raised its 2026 revenue guidance to over $145M and adjusted EBITDA margin to at …

Zurn Elkay Water Solutions (ZWS) Stock Looks Overvalued Relative To Earnings

Zurn Elkay Water Solutions (ZWS) has shown strong returns over five years, but its valuation is mixed. While a Discounted Cash Flow (DCF) model suggests the stock is undervalued by 10.9% relative to its intrinsic value, broader market multiples, particularly its P/E ratio of …

Relmada (RLMD) Q2 2026 Earnings Call Transcript

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20

BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.